StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Mizuho n Acadia Pharmaceuticals (ACAD): 'we view risk/reward as skewed significantly to the upside'
July 20, 2026 12:25 PM
Mizuho analyst Uy Ear reiterated an Outperform rating and $35.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst comments "This ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
